Chugai Pharmaceutical Co., Ltd. (CHGCY)

Market Cap	101.46B +38.6%
Revenue (ttm)	8.02B +7.5%
Net Income	2.77B +12.1%
EPS	1.68 +12.1%
Shares Out	n/a
PE Ratio	36.65
Forward PE	n/a
Dividend	1.81 (5.78%)
Ex-Dividend Date	Dec 29, 2025

Volume	15,508
Average Volume	312,424
Open	30.73
Previous Close	31.71
Day's Range	30.65 - 30.94
52-Week Range	19.50 - 34.84
Beta	0.46
RSI	57.62
Earnings Date	Apr 24, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 re...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1925
• Employees: 7,872
• Stock Exchange: OTCMKTS
• Ticker Symbol: CHGCY

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.

Financial numbers in JPY